Search research articles

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Simultaneous single-cell sequencing of RNA and DNA at scale with DEFND-seq.

Nature reviews. Genetics·2025

Same author

Scalable co-sequencing of RNA and DNA from individual nuclei.

Nature methods·2025

Same author

Scalable co-sequencing of RNA and DNA from individual nuclei.

bioRxiv : the preprint server for biology·2023

Same author

Microfluidic isolation of aptamers with affinity towards multiple myeloma monoclonal immunoglobulins.

Biomedical microdevices·2022

Same author

hiPSC Modeling of Lineage-Specific Smooth Muscle Cell Defects Caused by <i>TGFBR1</i><sup></sup> Variant, and Its Therapeutic Implications for Loeys-Dietz Syndrome.

Circulation·2021

Same author

A graphene aptasensor for biomarker detection in human serum.

Electrochimica acta·2021

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Dec 15, 2025

Recombinant Collagen I Peptide Microcarriers for Cell Expansion and Their Potential Use As Cell Delivery System in a Bioreactor Model

Recombinant Collagen I Peptide Microcarriers for Cell Expansion and Their Potential Use As Cell Delivery System in a Bioreactor Model

Published on: February 7, 2018

Bioreactor Parameters for Microcarrier-Based Human MSC Expansion under Xeno-Free Conditions in a Vertical-Wheel

Josephine Lembong¹, Robert Kirian¹, Joseph D Takacs¹

¹RoosterBio, Inc., 5295 Westview Drive, Suite 275, Frederick, MD 21703, USA.

Bioengineering (Basel, Switzerland)

|July 12, 2020

Summary

A new bioreactor process enables large-scale manufacturing of human mesenchymal stem/stromal cells (hMSCs). This optimized method ensures cell quality and quantity for commercial cell therapy demands.

Keywords:

bioprocess bioreactor hMSCs microcarrier

More Related Videos

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

Related Experiment Videos

Last Updated: Dec 15, 2025

Recombinant Collagen I Peptide Microcarriers for Cell Expansion and Their Potential Use As Cell Delivery System in a Bioreactor Model

Recombinant Collagen I Peptide Microcarriers for Cell Expansion and Their Potential Use As Cell Delivery System in a Bioreactor Model

Published on: February 7, 2018

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers

Published on: July 7, 2023

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

Area of Science:

Cell Biology
Biotechnology
Regenerative Medicine

Background:

Human mesenchymal stem/stromal cells (hMSCs) show therapeutic promise with over 900 clinical trials.
Commercial hMSC production requires large lot sizes (~100B cells), necessitating advanced manufacturing like 3D bioreactors.

Purpose of the Study:

To develop a scalable, cost-effective, and robust bioreactor process for clinical-grade hMSC manufacturing.
To optimize hMSC expansion in a suspension bioreactor system.

Main Methods:

Developed a fed-batch, microcarrier-based suspension bioreactor process.
Optimized parameters for inoculation, culture, and harvest stages.
Implemented a bioreactor feed strategy to replenish depleted mitogenic factors.

Main Results:

Achieved consistent hMSC densities of 2x10^5-6x10^5 cells/mL within 5 days without media exchange.
Maintained a final cell population doubling level (PDL) of 16-20.
Demonstrated process robustness across multiple hMSC donors, preserving cell characteristics and function.

Conclusions:

The developed fed-batch bioreactor process is scalable for commercial hMSC production.
This method enhances media productivity, reducing costs and labor.
The process yields high-quality hMSCs suitable for therapeutic applications.